Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma

Almagro-Casado, E.; Sánchez, Antonio; Cantos, Blanca; Salas, Clara; Pérez-Callejo, David; Provencio, Mariano

doi:10.1007/s12094-015-1342-7

Cited by 12 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, an increased incidence of skin and lung cancer is suggested to be related to exposure to radiotherapy, in particular in combination with systemic therapy [ 12 , 13 ]. This phenomenon is analogous to what has been observed among patients with Hodgkin lymphoma treated with radiotherapy [ 37 , 38 , 39 ].…”

Section: Discussionsupporting

confidence: 84%

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study

Dinnessen

Visser

Tonino

et al. 2020

eJHaem

View full text Add to dashboard Cite

We assessed the impact of a prior malignancy diagnosis (PMD) – as a potential proxy for genetic cancer susceptibility – on the development of a second primary malignancy (SPM) and mortality in follicular lymphoma (FL) patients. From the nationwide Netherlands Cancer Registry, we selected all adult FL patients diagnosed in 1994‐2012 (n = 8028) and PMDs and SPMs relative to FL, with follow‐up until 2017. We constructed two Fine and Gray models – with death as a competing risk – to assess the association between a PMD and SPM incidence. A PMD was associated with an increased incidence of SPMs (subdistribution hazard ratio [SHR], 1.30; 95% confidence interval [CI], 1.03‐1.64) – especially carcinomas of the respiratory tract (SHR, 1.83; 95% CI, 1.10‐3.05) and cutaneous squamous cell carcinomas (SHR, 1.58; 95% CI, 1.01‐2.45) – and a higher risk of mortality in a multivariable model (HR, 1.43; 95% CI, 1.19‐1.71). However, when additionally adjusted for the receipt of systemic therapy and/or radiotherapy before FL diagnosis, only patients who received such therapies had an increased incidence of SPMs (SHR, 1.40; 95% CI, 1.02‐1.93). In conclusion, patients with a PMD had a higher rate of SPMs and mortality than those without a PMD, which might have resulted from therapy‐related carcinogenesis.

show abstract

Section: Discussionsupporting

confidence: 84%

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study

Dinnessen

Visser

Tonino

et al. 2020

eJHaem

View full text Add to dashboard Cite

show abstract

“…Cigarette smoking increases second primary lung and tobacco‐associated cancer among survivors of Hodgkin lymphoma and cervical, breast, and urogenital cancers 23‐26 ; the elevated SMN risk in these survivors is likely due to the smoking prevalence 27 . Moreover, alcohol consumption and tobacco smoking heighten the risk of cancer in general 28 …”

Section: Discussionmentioning

confidence: 99%

Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population‐based cohort

Trama

Tittarelli

Barigelletti

et al. 2021

Cancer

View full text Add to dashboard Cite

Background Evidence about late effects in adolescent and young adult (AYA) cancer survivors is scarce. This study assessed the risk of subsequent malignant neoplasms (SMNs) to identify the most common SMNs to be considered in follow‐up care. Methods Population‐based cancer registries retrospectively identified first primary tumors (between 1976 and 2013) and SMNs in AYAs (15‐39 years old at their cancer diagnosis). AYA cancer survivors were those alive at least 5 years after their first cancer diagnosis. The excess risk of SMNs was measured as standardized incidence ratios (SIRs) and absolute excess risk together with the cumulative incidence of SMNs. Results The cohort included 67,692 AYA cancer survivors. The excess risk of developing any SMN (SIR, 1.6; 95% confidence interval, 1.5‐1.7) was 60%. The excess risk of SMNs was significantly high for survivors of lymphomas; cancers of the breast, thyroid, female genital tract, digestive organs, gonads, and urinary tract; and melanomas. The cumulative incidence of all SMNs in AYA cancer survivors within 25 years of their first cancer diagnosis was approximately 10%. Subsequent tumors contributing to approximately 60% of all SMNs were breast cancer, colorectal cancer, corpus uteri cancer, and ovarian cancer in females and colorectal cancer, bladder cancer, prostate cancer, lung cancer, and lymphomas in males. Conclusions These results highlight the need to personalize follow‐up strategies for AYA cancer survivors.

show abstract

“…Between the 1970s and 1990s, HL patients received extended-field radiation therapy (EFRT), which included mantle, extended mantle and subtotal nodal RT (figure 3). 5 It is well known that HL patients who have been treated with EFRT have an increased risk of developing subsequent malignancies 4 6–11. Several prospective studies have demonstrated that involved-field radiation therapy (IFRT) with 35 Gy RT for HL is as effective as EFRT with 35 Gy and reduces toxicities 12–14.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, chemotherapy and RT have dose-dependent and additive effects on the development of treatment-related lung cancer 11 19. Female patients who develop breast cancer as their treatment-related first primary malignancy have an increased risk of developing treatment-related second primary malignancies 6. Treatment-related lung cancers are diagnosed at either stage III or stage IV and are associated with poor outcomes 7 9.…”

Section: Discussionmentioning

confidence: 99%

Treatment-related peripheral small cell lung carcinoma in a Hodgkin lymphoma survivor

Gudapati

Abouamara

2022

BMJ Case Rep

View full text Add to dashboard Cite

Hodgkin lymphoma (HL) survivors have an increased risk of developing subsequent treatment-related primary malignancies. In the last few decades, advances in knowledge, radiotherapy, chemotherapy and autologous stem cell transplantation have led to the transformation of lethal malignancy into highly curable malignancy, thereby improving outcomes. With prolonged survival, the risk of developing subsequent treatment-related late adverse effects, such as malignancies, steadily increases over time. Herein, we present the first case of a treatment-related second primary stage IV peripheral small cell lung carcinoma in a female HL survivor who was also diagnosed with right breast cancer 13 years after HL treatment and 1 year before her lung cancer diagnosis.

show abstract

Lung cancer and other second neoplasms after treatment of Hodgkin lymphoma

Cited by 12 publications

References 27 publications

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study

The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study

Excess risk of subsequent malignant neoplasms in adolescent and young adult cancer survivors: Results from the first Italian population‐based cohort

Treatment-related peripheral small cell lung carcinoma in a Hodgkin lymphoma survivor

Contact Info

Product

Resources

About